论文部分内容阅读
目的:探讨苦参素联合甘利欣治疗慢性乙型肝炎的疗效,及对肝纤维化指标的影响。方法:选择我院200-01/2009-01收治的80例慢性乙型肝炎合并肝纤维化患者作为研究对象,随机分成治疗组和对照组各40例,治疗组给予甘利欣加苦参素,对照组应用复方丹参治疗,3个月为一个疗程。观察比较两组的临床疗效及肝功能指标与肝纤维化指标的改变。结果:治疗组40例的总有效率90.0%;对照组40例的总有效率为57.5%,两组总有效率比较,差异有统计学意义(P<0.05)。治疗前两组的肝纤维化指标HA、LN、PCⅢ、Ⅳ-C比较,差异无显著性,治疗3个月后,肝纤维化指标HA、LN、PCⅢ、Ⅳ-C均较治疗前明显下降,且治疗组与对照组比较,差异有统计学意义(P<0.05)。治疗前两组的肝功能指标ALT、AST、TBIL、ALB比较,差异无显著性,治疗3个月后,肝功能指标ALT、AST、TBIL、ALB比较均较治疗前明显下降,但治疗组与对照组比较,差异无显著性(P>0.05)。结论:苦参素和甘利欣对慢性乙型肝炎患者肝纤维化具有协同作用,阻止或改善肝纤维化有疗效明显,无明显副作用,值得临床推广和应用。
Objective: To investigate the curative effect of oxymatrine and glycyrrhizin in the treatment of chronic hepatitis B and its effect on the index of liver fibrosis. Methods: Eighty patients with chronic hepatitis B and hepatic fibrosis admitted in our hospital from January 2001 to January 2009 were selected and randomly divided into treatment group (40 cases) and control group (40 cases). The treatment group was treated with salmeterol, Control group application of compound Salvia treatment, 3 months for a course of treatment. The clinical efficacy, liver function and liver fibrosis were observed and compared between the two groups. Results: The total effective rate was 40.0% in the treatment group and 90.5% in the control group. The total effective rate in the two groups was statistically significant (P <0.05). There was no significant difference in HA, LN, PCⅢ, Ⅳ-C between the two groups before treatment, and the levels of HA, LN, PCⅢ and Ⅳ-C in liver fibrosis were significantly decreased 3 months after treatment , And the difference between the treatment group and the control group was statistically significant (P <0.05). There was no significant difference in ALT, AST, TBIL and ALB between the two groups before treatment. After 3 months of treatment, ALT, AST, TBIL and ALB were significantly decreased compared with before treatment The control group, the difference was not significant (P> 0.05). Conclusion: Oxymatrine and Glycyrrhizin have synergistic effects on liver fibrosis in patients with chronic hepatitis B, and there is obvious curative effect in preventing or improving liver fibrosis with no obvious side effects, which is worthy of clinical promotion and application.